Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report

TAÇOY, GÜLTEN; TÜRKOĞLU, Sedat; cengel, atiye; ÖZTÜRK, Zübeyde Nur

Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report

Gülten TAÇOY, (Gazi Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Atiye ÇENGEL, (Gazi Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Zübeyde Nur ÖZTÜRK, (Gazi Üniversitesi, Tıp Fakültesi, Onkoloji Anabilim Dalı, Ankara, Türkiye)

Sedat TÜRKOĞLU (Gazi Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Türk Kardiyoloji Derneği Arşivi

4 0

Yıl: 2015 Cilt: 43 Sayı: 1 Sayfa Aralığı: 78 - 81 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report

Öz:

Pulmoner hipertansiyon (HT) ortalama pulmoner arter basıncının 25 mmHgnin üzerine çıktığı patolojik durumdur. Pulmoner arteriyel hipertansiyon ise prekapiller pulmoner HT tipi olup, farklı etiyolojik nedenlere bağlı ortaya çıkan, benzer patolojik ve klinik bulgulara neden olan hayatı tehdit eden, pulmoner vasküler direncin yükselmesi ile karakterize bir durumdur. Dasatinib ikili Src/Abl kinaz inhibitörüdür ve imatinibe göre BCR/ABL kinaz afinitesi daha yüksektir ve kronik myelositik lösemide ve Filadelfiya kromozomu pozitif olan akut lenfoblastik lösemide (ALL) kullanılmaktadır. Biz ALL tedavisinde dasatinib kullanımına bağlı olarak pulmoner HT gelişen ve bosentan kullanımı ile düzelen olguyu tartışmayı amaçladık.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Akut lenfoblastik lösemili hastada dasatinib kullanımına bağlı pulmoner hipertansiyon: Olgu sunumu

Öz:

Summary Pulmonary hypertension (PHT) is a pathological condition determined as an increase in mean pulmonary ar- terial pressure ≥25 mmHg. Pulmonary arterial hypertension (PAH) is precapillary PHT and a life-threatening disease group which consists of different etiologies with the same pathological and clinical findings, and which is character- ized by elevated pulmonary vascular resistance. Dasatinib is a dual Src/Abl kinase inhibitor associated with higher af- finity for BCR/ABL kinase than imatinib, and is used in the treatment of chronic myelocytic leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). We describe a case with ALL, in whom dasatinib treatment induced PAH, and who recovered with bosentan treatment.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık

1. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243- 78.
2. Quintás-Cardama A, Kantarjian H, Obrien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-14.
3. Kantarjian H, Thomas D, OBrien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101:2788-801.
4. Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, et al. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol 2005;84:792-5.
5. Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110:4055-63.
6. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125:2128-37.
7. Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001;120:801-8.
8. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009;43:967-8.
9. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009;33:861-4.
10. Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 2011;11:30.
11. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, lowdose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 2012;36:e4-6.
12. Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011;38:218-20.

APA	TAÇOY G, cengel a, ÖZTÜRK Z, TÜRKOĞLU S (2015). Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. , 78 - 81.
Chicago	TAÇOY GÜLTEN,cengel atiye,ÖZTÜRK Zübeyde Nur,TÜRKOĞLU Sedat Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. (2015): 78 - 81.
MLA	TAÇOY GÜLTEN,cengel atiye,ÖZTÜRK Zübeyde Nur,TÜRKOĞLU Sedat Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. , 2015, ss.78 - 81.
AMA	TAÇOY G,cengel a,ÖZTÜRK Z,TÜRKOĞLU S Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. . 2015; 78 - 81.
Vancouver	TAÇOY G,cengel a,ÖZTÜRK Z,TÜRKOĞLU S Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. . 2015; 78 - 81.
IEEE	TAÇOY G,cengel a,ÖZTÜRK Z,TÜRKOĞLU S "Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report." , ss.78 - 81, 2015.
ISNAD	TAÇOY, GÜLTEN vd. "Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report". (2015), 78-81.

APA	TAÇOY G, cengel a, ÖZTÜRK Z, TÜRKOĞLU S (2015). Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. Türk Kardiyoloji Derneği Arşivi, 43(1), 78 - 81.
Chicago	TAÇOY GÜLTEN,cengel atiye,ÖZTÜRK Zübeyde Nur,TÜRKOĞLU Sedat Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. Türk Kardiyoloji Derneği Arşivi 43, no.1 (2015): 78 - 81.
MLA	TAÇOY GÜLTEN,cengel atiye,ÖZTÜRK Zübeyde Nur,TÜRKOĞLU Sedat Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. Türk Kardiyoloji Derneği Arşivi, vol.43, no.1, 2015, ss.78 - 81.
AMA	TAÇOY G,cengel a,ÖZTÜRK Z,TÜRKOĞLU S Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. Türk Kardiyoloji Derneği Arşivi. 2015; 43(1): 78 - 81.
Vancouver	TAÇOY G,cengel a,ÖZTÜRK Z,TÜRKOĞLU S Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. Türk Kardiyoloji Derneği Arşivi. 2015; 43(1): 78 - 81.
IEEE	TAÇOY G,cengel a,ÖZTÜRK Z,TÜRKOĞLU S "Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report." Türk Kardiyoloji Derneği Arşivi, 43, ss.78 - 81, 2015.
ISNAD	TAÇOY, GÜLTEN vd. "Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report". Türk Kardiyoloji Derneği Arşivi 43/1 (2015), 78-81.